A6X Stock Chart & Stats
€0.21
<€0.01(1.32%)
At close: 4:00 PM EST
€0.21
<€0.01(1.32%)
Day’s Range― - ―
52-Week Range€0.07 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€10.04M
Enterprise Value€83.71M
Total Cash (Recent Filing)€6.78M
Total Debt (Recent Filing)€3.09M
Price to Earnings (P/E)―
Beta-0.51
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding67,729,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)2.33
Price to Sales (P/S)6.68
P/FCF Ratio-7.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€3.53M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Acceleration (2025)The ~55% year-over-year revenue acceleration in 2025 signals improving commercial traction for phenylcapsaicin and validating end-market demand. Sustained top-line momentum creates a foundation to scale operations, attract partners, and justify incremental investment if converted into durable customer relationships.
Low Financial LeverageA low debt-to-equity ratio (~0.09) materially reduces refinancing and interest-rate risk, preserving financial optionality. This balance-sheet strength gives management time to commercialize products and seek non-dilutive partnerships or targeted financing while limiting near-term solvency pressure.
Proprietary Phenylcapsaicin PlatformOwning a proprietary active ingredient (phenylcapsaicin) with applications in feed and other capsaicinoid-relevant areas provides a durable competitive edge. The platform supports multiple commercial models—ingredient sales, finished formulations, or licensing—helping diversify long-term revenue pathways.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow have been negative across all reported years, indicating ongoing cash burn despite some 2025 improvement. Continued negative cash generation reduces internal funding capacity, raising the probability of dilutive raises or restrictive financing that could impair strategic execution.
Sustained Unprofitable MarginsDeeply negative gross and operating margins and recurrent net losses point to unfavorable unit economics or high fixed costs. Without structural margin improvement—through pricing, cost reduction, or mix shift—revenue growth alone may not achieve sustainable profitability, threatening long-term viability.
Eroding Equity And Negative ROEDeclining equity and materially negative returns on equity across years reflect capital erosion from operating losses. Continued equity depletion reduces the balance-sheet buffer, increases reliance on external capital, and heightens risk of dilution or constrained investment capacity if profitability isn't restored.
aXichem AB Class A News
A6X FAQ
What was aXichem AB Class A’s price range in the past 12 months?
aXichem AB Class A lowest stock price was €0.07 and its highest was €0.32 in the past 12 months.
What is aXichem AB Class A’s market cap?
aXichem AB Class A’s market cap is €10.04M.
When is aXichem AB Class A’s upcoming earnings report date?
aXichem AB Class A’s upcoming earnings report date is Aug 27, 2026 which is in 56 days.
How were aXichem AB Class A’s earnings last quarter?
aXichem AB Class A released its earnings results on May 21, 2026. The company reported -€0.012 earnings per share for the quarter, the consensus estimate of -€0.012 by €0.
Is aXichem AB Class A overvalued?
According to Wall Street analysts aXichem AB Class A’s price is currently Overvalued.
Does aXichem AB Class A pay dividends?
aXichem AB Class A does not currently pay dividends.
What is aXichem AB Class A’s EPS estimate?
aXichem AB Class A’s EPS estimate is -0.01.
How many shares outstanding does aXichem AB Class A have?
aXichem AB Class A has 67,729,120 shares outstanding.
What happened to aXichem AB Class A’s price movement after its last earnings report?
aXichem AB Class A reported an EPS of -€0.012 in its last earnings report, expectations of -€0.012. Following the earnings report the stock price went up 4.301%.
Which hedge fund is a major shareholder of aXichem AB Class A?
Currently, no hedge funds are holding shares in DE:A6X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
aXichem AB Class A
aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.
Technical Analysis
Nexam Chemical Holding AB
―
―
Svenska Aerogel Holding AB
―
OrganoClick AB
―
XP Chemistries AB
―